Axsome Therapeutics (AXSM) Cash from Financing Activities (2015 - 2026)

Axsome Therapeutics has reported Cash from Financing Activities for 12 years, with the latest figure at $3.0 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 89.77% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.2 million (down 14.85% YoY) and the FY2025 annual result came in at $101.5 million, up 75.42% from the prior year.
• Cash from Financing Activities slipped to $3.0 million in Q1 2026 per AXSM's latest filing, from $16.4 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $246.1 million in Q2 2023 and troughed at -$1.2 million in Q1 2024.
• A 5-year average of $45.8 million and a median of $29.3 million in 2025 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 712300.0% in 2024, down 102.3% in 2024.
• Over 5 years, Cash from Financing Activities stood at $1.1 million in 2022, then plunged by 100.19% to -$2000.0 in 2023, then jumped by 712300.0% to $14.2 million in 2024, then grew by 15.03% to $16.4 million in 2025, then slumped by 81.73% to $3.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.0 million, $16.4 million, and $21.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.